Want to track GOSS and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
Oppenheimer initiated coverage on Gossamer Bio Inc GOSS, a clinical-stage biopharmaceutical company, with an Outperform rating and a price target of $9.
Benzinga | 2 years ago
The Penny Stock Pundits: 3 Companies Poised to Become the Talk of Wall Street
Do you have any penny stocks in your portfolio? If you don't, you might want to consider it with any speculative money sitting on the sidelines.
Investorplace | 2 years ago
